Meeting
2017 ASCO Annual Meeting
A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy.
Authors
Ji-Yeon Kim
Samsung Medical Center, Seoul, Republic of Korea
Ji-Yeon Kim , Oh-Nam Ok , Jeong Ju Seo , Soo-Hyeon Lee , Jin Seok Ahn , Yeon Hee Park
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT02670603
Citation
J Clin Oncol 35, 2017 (suppl; abstr 10108)
DOI
10.1200/JCO.2017.35.15_suppl.10108
Abstract #
10108
Poster Bd #
97
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.
First Author: Douglas W. Blayney
Poster
2014 ASCO Annual Meeting
ABCB1 polymorphism as a prognostic factor in breast cancer patients with neoadjuvant chemotherapy.
First Author: Hee Jun Kim
Poster
2013 ASCO Annual Meeting
Sixteen years follow-up results of a randomized phase II trial of neoadjuvant FAC compared with CMF in stage III breast cancer.
First Author: Ariel Osvaldo Zwenger
Poster
2012 ASCO Annual Meeting
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy (NACT) for early breast cancer: Three-year follow-up data.
First Author: Andreas Schneeweiss